Search
Filters
Clear All
  • 6
  • 13
  • 143

Phase

  • 5
  • 4
  • 17
  • 2
  • 8
  • 116
  • 154
  • 58

Found 162 Cancer trials

A listing of Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

A multi-center phase Ib trial evaluating the safety and efficacy of lacutamab in patients with relapse peripheral T-cell lymphoma that express KIR3DL2

U
Utpal Dave, MD
18-100 years
All genders
Phase 1/2
A multi-center phase Ib trial evaluating the safety and efficacy of lacutamab in patients with relapse peripheral T-cell lymphoma that express KIR3DL2.
Learn More

A Phase 1/2 Trial of VX15/2503 in Children Adolescents or Young Adults With Recurrent or Relapsed Solid Tumors

J
James Croop, MD, PhD
1-30 years
All genders
This phase I/II trial studies the side effects and best dose of anti-SEMA4D monoclonal antibody VX15/2503 (VX15/2503) and to see how well it works in treating younger patients with solid tumors that have come back after treatment, or do not respond to treatment.
Learn More

A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia

S
Sandeep Batra, MD
8-15 years
All genders
This randomized clinical trial studies how well web-based physical activity intervention works in improving long term health in children and adolescents with newly diagnosed acute lymphoblastic leukemia that shows a decrease in or disappearance of signs and symptoms. Regular physical activity after receiving treatment for cancer may help to maintain …
Learn More

Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder (ADAPT)

N
Nabil Adra, MD
18-100 years
All genders
The main purpose of this phase 1 trial is to show that durvalumab is safe when given alone, in combination with BCG treatments, and in combination with radiation therapy. The overall goal of this trial is to see if the risk of your cancer coming back can be decreased with …
Learn More

A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors

G
Greg Durm, MD
18-100 years
All genders
Phase 1/2
To determine the recommended Phase 2 dose (RP2D) of LY3537982 monotherapy in patients with KRAS G12C-mutant advanced solid tumors
Learn More

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

S
Shadia Jalal, MD
18 years and older
All genders
Phase 2/3
Interventional
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruingultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer(biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to …
Learn More

A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-Like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations

S
Sandeep Batra, MD
1-30 years
All genders
This randomized phase III trial is studying how well combination chemotherapy works in treating young patients with newly diagnosed acute lymphoblastic leukemia that is likely to come back or spread.
Learn More

Perioperative Pelvic Floor Muscle Training May Improve Recovery of Continence in Men with Localized Prostate Cancer Undergoing Robot-Assisted Radical Prostatectomy

R
Ronald Boris, MD
18-100 years
Male
The purpose of this study is to determine if pelvic floor muscle training with a physical therapist before and after surgery will improve health-related quality of life following robot-assisted radical prostatectomy.
Learn More

A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination with Anti-PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors

S
Shadia Jalal, MD
18-100 years
All genders
The purpose of this study is to evaluate the safety of the study drug LY3381916 administered alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody (LY3300054).
Learn More

Pembrolizumab in MIBC

N
Nabil Adra, MD
18 years and older
All genders
Phase 2
Interventional
Subjects with cT2-T3N0M0 urothelial cancer of the bladder will be enrolled. After completingwo cycles of pembrolizumab, subjects will undergo a restaging MRI of the abdomen and pelvis with a standard acquisition protocol (as outlined in the protocol) as well as CT chest. A CThe abdomen and pelvis may be performed …
Learn More
101 - 110 of 162